Mohammed Jemal
Overview
Explore the profile of Mohammed Jemal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Adugna A, Muche Y, Melkamu A, Jemal M, Belew H, Amare G
Heliyon
. 2024 Aug;
10(14):e34288.
PMID: 39100497
Liver cancer caused by the hepatitis B virus (HBV) is the third most common cancer-related cause of death worldwide. Early detection of HBV-caused hepatic tumors increases the likelihood of a...
12.
Waritu N, Nair S, Usure R, Jemal M
Front Med (Lausanne)
. 2024 Aug;
11:1370725.
PMID: 39086939
Background: After the introduction of antiretroviral therapy, the care given to people living with HIV has become complicated by the appearance of comorbidities as a result of HIV and HAART...
13.
Mengistu E, Malik D, Molla M, Adugna A, Jemal M
Heliyon
. 2024 Jul;
10(12):e33054.
PMID: 38988551
Background: Recently, dolutegravir-based therapy has become the first-line treatment when compared to others. However, dolutegravir-associated side effects in the liver and levels of efficacy haven't been addressed yet in underdeveloped...
14.
Jemal M
SAGE Open Med
. 2024 Jun;
12:20503121241260613.
PMID: 38881592
Dolutegravir is an integrase inhibitor and is recommended by the World Health Organization as the preferred first-line and second-line human immunodeficiency virus treatment in all populations. Excessive weight gain associated...
15.
Baylie T, Tsega W, Getinet M, Abebaw D, Azanaw G, Adugna A, et al.
Metabol Open
. 2024 Jun;
22:100286.
PMID: 38828006
Background: The leaves of have been used traditionally for the management of diabetes mellitus. Thus, this study aimed to evaluate the Antioxidant and Antihyperglycemic Effects of leaves crude extract in...
16.
Baylie T, Kasaw M, Getinet M, Getie G, Jemal M, Nigatu A, et al.
Front Oncol
. 2024 May;
14:1374821.
PMID: 38812786
Breast cancer (BC) is the second most common cause of deaths reported in women worldwide, and therefore there is a need to identify BC patients at an early stage as...
17.
Tefera M, Mezmur H, Jemal M, Assefa N
BMJ Open
. 2024 Apr;
14(4):e075263.
PMID: 38658007
Objective: The purpose of this exploratory study was to assess healthcare providers' perspectives on maternity care following the introduction of ultrasound services in the area. Design: The qualitative descriptive study....
18.
Akinaw M, Nair S, Usure R, Leta B, Kedir A, Mamo S, et al.
J Exp Pharmacol
. 2024 Apr;
16:159-171.
PMID: 38596746
Background: Drug-induced kidney injury was among the most common renal damages, from which gentamicin occupies around 25% of this injury. Gentamicin-induced renal damage is caused by increased free radicals with...
19.
Adugna A, Muche Y, Jemal M, Habtegiorgis S, Belew H, Amare G
Aging Med (Milton)
. 2024 Apr;
7(1):121-130.
PMID: 38571678
Lung cancer (LC) is the most common cause of cancer-related death worldwide and poses a severe threat to public health. Immunotherapy with checkpoint blockers has improved the outlook for advanced...
20.
Waritu N, Nair S, Birhan B, Adugna T, Awgichew G, Jemal M
HIV AIDS (Auckl)
. 2024 Feb;
16:17-32.
PMID: 38369986
Background: Long-term use of antiretroviral therapy, especially dolutegravir and boosted-atazanavir, raises concerns about cardiovascular disease. Thus, this study aimed to assess lipid profiles, blood glucose, and high-sensitivity C-reactive protein levels...